Osteoarthritis: from pathogenic mechanisms and recent clinical developments to novel prospective therapeutic options

Drug Discov Today. 2016 Dec;21(12):1932-1937. doi: 10.1016/j.drudis.2016.08.011. Epub 2016 Sep 8.

Abstract

Osteoarthritis (OA) is a degenerative joint disease that, despite recent progress, has no curative treatment. Considerable research has recently been initiated to identify new potential therapeutic targets. In this review, we will set forth some of the major discoveries in the past 5 years, notably those dealing with the identification of pathogenic factors [hypoxia-inducible factors (HIFs), complement, transforming growth factor (TGF)-β and zinc-ZIP8]. New drugs and concepts currently in clinical development [anti-nerve growth factor (NGF), mesenchymal stromal cells and fibroblast growth factor (FGF)-18] will then be addressed. Finally, we will consider prospective avenues that could lead to mid-to-long-term developments of novel therapeutic concepts, notably those dealing with autophagy regulation and induced pluripotent stem cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Complement System Proteins / metabolism
  • DNA-Binding Proteins / metabolism
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Osteoarthritis* / drug therapy
  • Osteoarthritis* / etiology
  • Osteoarthritis* / metabolism
  • Osteoarthritis* / therapy
  • Transcription Factor MTF-1
  • Transcription Factors / metabolism
  • Transforming Growth Factor beta / metabolism

Substances

  • DNA-Binding Proteins
  • HIF1A protein, human
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Transcription Factors
  • Transforming Growth Factor beta
  • Complement System Proteins